A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Bevacizumab (Primary) ; Interferon alpha-2b
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 24 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 30 May 2014 Biomarker analysis presented at 50th Annual Meeting of the American Society of Clinical Oncology.